Cara Therapeutics Reports Second Quarter 2021 Financial Results
August 09, 2021 16:01 ET
|
Cara Therapeutics, Inc.
– New Drug Application (NDA) Filing for KORSUVA™ Injection in CKD-aP under Priority Review by U.S. Food and Drug Administration (FDA); PDUFA Target Action Date August 23, 2021 – – Conference call...
Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021
August 02, 2021 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics to Present at the Jefferies Healthcare Conference
May 25, 2021 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., May 25, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Reports First Quarter 2021 Financial Results
May 10, 2021 16:01 ET
|
Cara Therapeutics, Inc.
– U.S. Food and Drug Administration (FDA) Accepts New Drug Application (NDA) Filing and Grants Priority Review for KORSUVA™ Injection in CKD-aP – – Conference call today at 4:30 p.m. ET – STAMFORD,...
Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
May 06, 2021 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., May 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
May 03, 2021 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
April 29, 2021 07:00 ET
|
Cara Therapeutics, Inc.
– Study did not meet Primary Endpoint of worst-itch NRS change from baseline at week 12 or Secondary Endpoint of 4-point responder analysis in the ITT patient population – Study...
Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference
April 07, 2021 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics to Host Virtual Research and Development Event on April 7, 2021
March 31, 2021 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
March 30, 2021 01:00 ET
|
Cara Therapeutics, Inc.
Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalinIf approved, difelikefalin injection will be the first therapy available in Europe for...